Selectis Health Appoints New Director, Announces Officer Compensation Details
Ticker: GBCS · Form: 8-K · Filed: Aug 29, 2024 · CIK: 727346
| Field | Detail |
|---|---|
| Company | Selectis Health, Inc. (GBCS) |
| Form Type | 8-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $180,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, executive-compensation
TL;DR
Selectis Health swapped a director and is talking officer pay.
AI Summary
Selectis Health, Inc. announced on August 27, 2024, the departure of Director Michael J. O'Donnell and the appointment of new Director David J. Scholl. The company also reported on compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are crucial for understanding executive incentives.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can impact investor confidence and signal potential strategic shifts.
Key Players & Entities
- Selectis Health, Inc. (company) — Registrant
- Michael J. O'Donnell (person) — Departing Director
- David J. Scholl (person) — Appointed Director
FAQ
Who has departed from the Board of Directors?
Michael J. O'Donnell has departed from the Board of Directors.
Who has been appointed to the Board of Directors?
David J. Scholl has been appointed to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is August 27, 2024.
What is the state of incorporation for Selectis Health, Inc.?
Selectis Health, Inc. is incorporated in Utah.
What were Selectis Health, Inc.'s former names?
Selectis Health, Inc. was formerly known as Global Healthcare REIT, Inc., Global Casinos Inc, and Morgro Chemical Co.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-08-29 17:07:30
Key Financial Figures
- $180,000 — 2, 2023. Mr. Creamer's base salary is $180,000 per year. A copy of the Company's and
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex10-1.htm (EX-10.1) — 2KB
- ex10-1_001.jpg (GRAPHIC) — 7976KB
- ex10-1_002.jpg (GRAPHIC) — 216KB
- 0001493152-24-034418.txt ( ) — 11483KB
- gbcs-20240827.xsd (EX-101.SCH) — 3KB
- gbcs-20240827_lab.xml (EX-101.LAB) — 33KB
- gbcs-20240827_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 SELECTIS HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Utah 0-15415 87-0340206 (State or other jurisdiction of incorporation) Commission File Number (I.R.S. Employer Identification number) 8480 E. Orchard Road , Ste. 4900 , Greenwood Village , CO 80111 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (720) 680-0808 (Former name or former address, if changed since last report) Written communications pursuant to Rule 425 under the Securities Act Soliciting material pursuant to Rule 14a-12 under the Exchange Act Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act Securities registered pursuant to Section 12(b) of the Act: Title of each Class Trading Symbol Name of each exchange on which registered N/A N/A N/A Indicate by check mark whether the registrant is an emerging growth company as dened in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised nancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ITEM 5.02 ELECTIONOF DIRECTORS; APPPOINTMENT OF CERTAIN OFFICERS Appointment of Jim Creamer as Chief Financial Officer On August 27, 2024 the Board of Directors of Selectis Health, Inc., a Utah corporation (the "Company") approved the appointment of James Creamer to the position of Chief Financial Officer, effective August 15, 2024. Mr. Creamer has been serving as the Company's Interim CEO since December of 2023, as previously reported on the Company's Current Report on Form 8-K dated December 18, 2023 and filed with SEC on December 22, 2023. Mr. Creamer's base salary is $180,000 per year. A copy of the Company's and Mr. Creamer's fully executed Offer Letter setting forth the terms of Mr. Creamer's engagement is filed herewith as Exhibit 10.1 ITEM 9.01 EXHIBITS Item Title 10.1 Offer Letter 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Selectis Health, Inc. (Registrant) Dated: August 29, 2024 /s/ Adam Desmond Adam Desmond, CEO